NEWER DRUGS FOR VISCERAL LEISHMANIASIS: A REVIEW
Krishna Pandey1, Dharmendra Singh1, Sanjiva Bimal1, Vidyanand Rabidas1, Krishna Murti1, Chadrashekhar Lal2 & P. Das1 Show affiliations
- Rajendra Memorial Research Institute of Medical Sciences, India
- National Institute of Pharmaceutical Education and Research, India
American Journal of Infectious Diseases, Volume 10, Issue 2, pp. 68–70 · doi.org/10.3844/ajidsp.2014.68.70
Abstract
Visceral Leishmaniasis (VL) is one of the most neglected tropical diseases worldwide. The diagnosis and treatment of this disease is quite complex. Sodium Antimony Gluconate (SAG) which used to be a very effective treatment has now developed resistance and is potentially a cardio-toxic drug. Pentamidine has now been discarded because of adverse effect of diabetes mellitus. Amphotericin-B is an effective drug but can cause nephrotoxicity. Miltefosine is a new oral effective drug which has recently been introduced in the kala-azar elimination program in the Indian subcontinent. Paromomycin is an injectable aminoglycoside which is quite cheap but can cause ototoxicity and nephrotoxicity. Sitamaquine, an oral antimalarial drug is still in phase-II trial stage. Combination Therapy is been tried with good results. Single dose Ambisome (liposomal Amphotericin-B) though costly is a very good alternative.
Licence and reuse
Free to read. This article carries the publisher’s copyright, as printed on it: © 2014 Science Publications. It is free to read; ask us before reusing it.
How to reuse this articleResponses (0)
About this article
Pandey, K., Singh, D., Bimal, S., Rabidas, V., Murti, K., Lal, C. & Das, P. (2014). NEWER DRUGS FOR VISCERAL LEISHMANIASIS: A REVIEW. American Journal of Infectious Diseases, 10(2), 68–70. https://doi.org/10.3844/ajidsp.2014.68.70
- Licence
- © Science Publications
- Issue
- Volume 10, Issue 2
- Policies
- Editorial independenceUse of generative AIData availabilityAppeals and complaints
- Version
- Version of record
